Proteintech

Proteintech is a well-established, revenue-generating life sciences reagent company with a broad portfolio centered on antibodies and associated proteins. The company has strategically pivoted from traditional polyclonal antibodies to a strong focus on recombinant monoclonal antibody technology, positioning itself at the forefront of reproducibility and innovation in research tools. Its expansion into cGMP-grade proteins, nanobody-based reagents, and specialized kits for cell & gene therapy demonstrates a clear growth strategy into adjacent high-value markets. With a significant citation record and a global customer base, Proteintech is a major player in the research tools sector, competing on quality, technological innovation, and breadth of catalog.

Proprietary recombinant antibody production platform (ABC platform) for generating Uni-rAb (monoclonal), Multi-rAb (multi-clonal mixtures), and FcZero-rAb antibodies. Also utilizes human cell expression (HumanKine) for proteins and develops nanobody (VHH)-based reagents.

Proteintech competes in the crowded life sciences reagent market against giants like Thermo Fisher Scientific, Abcam (now part of Danaher), and Bio-Techne, as well as specialized players like Cell Signaling Technology. It differentiates through its strong focus on recombinant technology, a very broad target catalog, and its strategic push into cGMP materials for therapy development.